Cancer Cachexia, Mechanism and Treatment

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 4, 2015, Pages 17-29

  Aoyagi, Tomoyoshi ^a,b   Terracina, Krista P ^a   Raza, Ali ^a   Matsubara, Hisahiro ^b   Takabe, Kazuaki ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Cancer cachexia; Pharmacological treatment; Physical exercise

Indexed keywords

EID: 85011630556     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i4.17     Document Type: Article

References (193)

1. 1 Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410 [PMID: 19342610 DOI: 10.1152/physrev.00016.2008]
2. 2 Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10: 90-99 [PMID: 23207794 DOI: 10.1038/nrclinonc.2012.209]
3. 3 Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495 [PMID: 21296615 DOI: 10.1016/S1470-2045(10)70218-7]
4. 4 Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F,Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr 2008; 27: 793-799 [PMID: 18718696 DOI: 10.1016/j.clnu.2008.06.013]
5. 5 Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 862-871 [PMID: 12415256 DOI: 10.1038/nrc927]
6. 6 Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc Nutr Soc 1999; 58: 321-328 [PMID: 10466173]
7. 7 von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009; 121: 227-252\ [PMID: 19061914 DOI: 10.1016/j.pharmthera.2008.09.009]
8. 8 Giordano A, Calvani M, Petillo O, Carteni’ M, Melone MR, Peluso G. Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem 2003; 90: 170-186 [PMID: 12938166 DOI: 10.1002/jcb.10601]
9. 9 Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69: 491-497 [PMID: 7424938]
10. 10 Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005; 8: 265-269 [PMID: 15809528]
11. 11 Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11: 400-407 [PMID: 18541999 DOI: 10.1097/MCO.0b013e328300ecc1]
12. 12 Warren S. The immediate cause of death in cancer. Am J Med Sci 1932; 184: 610-613
13. 13 Skipworth RJ, Stewart GD, Dejong CH, Preston T, Fearon KC. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007; 26: 667-676 [PMID: 17507116 DOI: 10.1016/j.clnu.2007.03.011]
14. 14 Hopkinson JB, Wright DN, McDonald JW, Corner JL. The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage 2006; 32: 322-331 [PMID: 17000349 DOI: 10.1016/j.jpainsymman.2006.05.01 2]
15. 15 von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010; 1: 1-5 [PMID: 21475699 DOI: 10.1007/ s13539-010-0002-6]
16. 16 Diffee GM, Kalfas K, Al-Majid S, McCarthy DO. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol-Cell Ph 2002; 283: C1376-C1382 [PMID: 12372798 DOI: 10.1152/ajpcell.00154.2002]
17. 17 Tijerina AJ. The biochemical basis of metabolism in cancer cachexia. Dimens Crit Care Nurs 2004; 23: 237-243 [PMID: 15586034]
18. 18 Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34: 94-104 [PMID: 17509812 DOI: 10.1016/j.jpainsymman.2006.10.015]
19. 19 Argilés JM. Cancer-associated malnutrition. Eur J Oncol Nurs 2005; 9 Suppl 2: S39-S50 [PMID: 16437757 DOI: 10.1016/j.ejon.2005.09.006]
20. 20 Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer 2010; 18: 1-9 [PMID: 19688225 DOI: 10.1007/s00520-009-0722-3]
21. 21 Springer J, von Haehling S, Anker SD. The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endoc 2006; 2: 416-417 [PMID: 16932326 DOI: 10.1038/ncpendmet0247]
22. 22 Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: Common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol 2008; 101: 8E-10E [PMID: 18514632 DOI: 10.1016/j.amjcard.2008.02.065]
23. 23 Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010; 267: 543-560 [PMID: 20210843 DOI: 10.1111/j.1365-2796.2010.02218.x]
24. 24 Argilés JM, Busquets S, Toledo M, López-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009; 3: 263-268 [PMID: 19713854 DOI: 10.1097/SPC.0b013e3283311d09]
25. 25 MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE. Understanding and managing cancer cachexia. J Am Coll Surg 2003; 197: 143-161 [PMID: 12831935 DOI: 10.1016/S1072-7515(03)00382-X]
26. 26 Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, Kaasa S, Fearon K, Strasser F. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol 2011; 80: 114-144 [PMID: 21216616 DOI: 10.1016/j.critrevonc.2010.10.004]
27. 27 Deans DA, Tan BH, Wigmore SJ, Ross JA, de Beaux AC, Paterson- Brown S, Fearon KC. The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br J Cancer 2009; 100: 63-69 [PMID: 19127266 DOI: 10.1038/sj.bjc.6604828]
28. 28 Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 1999; 23: 584-588 [PMID: 10227928]
29. 29 Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221 [PMID: 16642000 DOI: 10.1038/nature04672]
30. 30 Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995; 13: 2600-2605 [PMID: 7595713]
31. 31 Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 1996; 73: 1560-1562 [PMID: 8664130]
32. 32 Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322 [PMID: 1596890]
33. 33 Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, Carter DC. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995; 75: 2077-2082 [PMID: 7535184]
34. 34 O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998; 32: 76-80 [PMID: 9919615 DOI: 10.1080/01635589809514722]
35. 35 Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 1999; 35: 106-110 [PMID: 10693162 DOI: 10.1207/ S15327914NC352_2]
36. 36 Reeds PJ, Fjeld CR, Jahoor F. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states? J Nutr 1994; 124: 906-910 [PMID: 7515956]
37. 37 Barber MD, Fearon KC, McMillan DC, Slater C, Ross JA, Preston T. Liver export protein synthetic rates are increased by oral meal feeding in weight-losing cancer patients. Am J Physiol Endocrinol Metab 2000; 279: E707-E714 [PMID: 10950840]
38. 38 Ross JA, Fearon KC. Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 2002; 5: 241-248 [PMID: 11953648]
39. 39 Tisdale MJ. The ‘cancer cachectic factor’. Support Care Cancer 2003; 11: 73-78 [PMID: 12560934 DOI: 10.1007/s00520-002-0408-6]
40. 40 Baracos VE, Mazurak VC, Ma DW. n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev 2004; 17: 177-192 [PMID: 19079925 DOI: 10.1079/ NRR200488]
41. 41 Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-543 [PMID: 20723755 DOI: 10.1016/j.cell.2010.07.011]
42. 42 Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010; 391: 1548-1554 [PMID: 20036643 DOI: 10.1016/j.bbrc.2009.12.123]
43. 43 Murphy KT, Chee A, Gleeson BG, Naim T, Swiderski K, Koopman R, Lynch GS. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol 2011; 301: R716-R726 [PMID: 21677277 DOI: 10.1152/ajpregu.00121.2011]
44. 44 Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153-166 [PMID: 22795476 DOI: 10.1016/j.cmet.2012.06.011]
45. 45 Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, Steiner MS. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011; 62: 265-279 [PMID: 20731602 DOI: 10.1146/annurevmed- 061509-131248]
46. 46 Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 2010; 38: 168-176 [PMID: 20871233 DOI: 10.1097/JES.0b013e3181f44f11]
47. 47 Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998; 25: 53-57 [PMID: 9625384]
48. 48 Mantovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998; 25: 45-52 [PMID: 9625383]
49. 49 Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997; 89: 1763-1773 [PMID: 9392617]
50. 50 Plata-Salamán CR. Immunoregulators in the nervous system. Neurosci Biobehav Rev 1991; 15: 185-215 [PMID: 1852312]
51. 51 Plata-Salamán CR. Anorexia during acute and chronic disease. Nutrition 1996; 12: 69-78 [PMID: 8724375]
52. 52 Moldawer LL, Copeland EM. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 1997; 79: 1828-1839 [PMID: 9129003]
53. 53 Banks WA. Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier. Nutrition 2001; 17: 434-437 [PMID:11377145]
54. 54 Hellerstein MK, Meydani SN, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest 1989; 84: 228-235 [PMID: 2786888 DOI: 10.1172/JCI114145]
55. 55 Torelli GF, Meguid MM, Moldawer LL, Edwards CK, Kim HJ, Carter JL, Laviano A, Rossi Fanelli F. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol 1999; 277: R850-R855 [PMID: 10484503]
56. 56 Yeh SS, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr 1999; 70: 183-197 [PMID: 10426694]
57. 57 Laviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Rossi Fanelli F. Cracking the riddle of cancer anorexia. Nutrition 1996; 12: 706-710 [PMID: 8936495]
58. 58 Picton SV. Aspects of altered metabolism in children with cancer. Int J Cancer Suppl 1998; 11: 62-64 [PMID: 9876481]
59. 59 Albrecht JT, Canada TW. Cachexia and anorexia in malignancy. Hematol Oncol Clin North Am 1996; 10: 791-800 [PMID: 8811301]
60. 60 Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/ IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012; 122: 143-159 [PMID: 22029668 DOI: 10.1042/CS20110340]
61. 61 Barber MD, Fearon KC, Tisdale MJ, McMillan DC, Ross JA. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 2001; 40: 118-124 [PMID: 11962246 DOI: 10.1207/S15327914NC402_7]
62. 62 Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988; 80: 595-598 [PMID: 3373550]
63. 63 Falconer JS, Ross JA, Fearon KC, Hawkins RA, O’Riordain MG, Carter DC. Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 1994; 69: 826-832 [PMID: 8180010]
64. 64 Spitzner M, Ebner R, Wolff HA, Ghadimi BM, Wienands J, Grade M. STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Cancers (Basel) 2014; 6: 1986-2011 [PMID: 25268165 DOI: 10.3390/cancers6041986]
65. 65 Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, Zimmers TA. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012; 303: E410-E421 [PMID: 22669242 DOI: 10.1152/ajpendo.00039.2012]
66. 66 Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011; 2011: 601434 [PMID: 21760776 DOI: 10.1155/2011/601434]
67. 67 Argilés JM, Moore-Carrasco R, Fuster G, Busquets S, López- Soriano FJ. Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 2003; 35: 405-409 [PMID: 12565701]
68. 68 Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell mass in cancer-bearing and anorexic patients. JPEN J Parenter Enteral Nutr 1987; 11: 219-222 [PMID: 3474427]
69. 69 Dworzak F, Ferrari P, Gavazzi C, Maiorana C, Bozzetti F. Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover. Cancer 1998; 82: 42-48 [PMID: 9428478]
70. 70 Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 2001; 6: D164-D174 [PMID: 11171557]
71. 71 Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114: 370-378 [PMID: 15286803 DOI: 10.1172/JCI20174]
72. 72 Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013; 4: 95-109 [PMID: 23097000 DOI: 10.1007/ s13539-012-0087-1]
73. 73 Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyenfeldt MF, Saris WH. Effect of different tumor types on resting energy expenditure. Cancer Res 1991; 51: 6138-6141 [PMID: 1657379]
74. 74 Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 325-331 [PMID: 7512810]
75. 75 Rigaud D, Hassid J, Meulemans A, Poupard AT, Boulier A. A paradoxical increase in resting energy expenditure in malnourished patients near death: the king penguin syndrome. Am J Clin Nutr 2000; 72: 355-360 [PMID: 10919927]
76. 76 Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 1986; 111: 82-85 [PMID: 3949854]
77. 77 Qualliotine-Mann D, Agwu DE, Ellenburg MD, McCall CE, McPhail LC. Phosphatidic acid and diacylglycerol synergize in a cell-free system for activation of NADPH oxidase from human neutrophils. J Biol Chem 1993; 268: 23843-23849 [PMID: 8226922]
78. 78 Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 2000; 60: 2405-2410 [PMID: 10811117]
79. 79 Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br J Cancer 2002; 86: 372-375 [PMID: 11875702 DOI: 10.1038/sj.bjc.6600074]
80. 80 Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, Tschetter LK, Hatfield AK, Morton RF. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11: 762-767 [PMID: 8478668]
81. 81 Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279-1282 [PMID: 2205358]
82. 82 Neri B, Garosi VL, Intini C. Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 1997; 8: 459-465 [PMID: 9215608]
83. 83 Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol 2000; 27: 64-68 [PMID: 10697022]
84. 84 Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55: 675-688 [PMID: 9585863]
85. 85 Argilés JM, Meijsing SH, Pallarés-Trujillo J, Guirao X, López- Soriano FJ. Cancer cachexia: a therapeutic approach. Med Res Rev 2001; 21: 83-101 [PMID: 11135301]
86. 86 Feliu J, González-Barón M, Berrocal A, Ordóñez A, Barón-Saura JM. Treatment of cancer anorexia with megestrol acetate: which is the optimal dose? J Natl Cancer Inst 1991; 83: 449-450 [PMID: 1999853]
87. 87 Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, Mailliard JA, Johnson PS, Ebbert LP, Geeraerts LH. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127-1132 [PMID: 2193166]
88. 88 Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, Aisner J. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992; 69: 1268-1274 [PMID: 1739926]
89. 89 Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993; 11: 152-154 [PMID: 8418227]
90. 90 Rowland KM, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, Owen D, Washburn JH, Webb TA, Mailliard JA, Jett JR. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996; 14: 135-141 [PMID: 8558188]
91. 91 Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia- cachexia syndrome. Cochrane Database Syst Rev 2013; 3: CD004310 [PMID: 23543530 DOI: 10.1002/14651858.CD004310. pub3]
92. 92 McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994; 265: 99-102 [PMID: 7883035]
93. 93 Mantovani G, Macciò A, Massa E, Madeddu C. Managing cancerrelated anorexia/cachexia. Drugs 2001; 61: 499-514 [PMID: 11324680]
94. 94 Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. Highdose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 2001; 12: 289-300 [PMID: 11332139]
95. 95 Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Massa E, Dessì D, Melis GB, Del Giacco GS. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1997; 33: 602-607 [PMID: 9274442]
96. 96 Costa AM, Spence KT, Plata-Salamán CR, ffrench-Mullen JM. Residual Ca2+ channel current modulation by megestrol acetate via a G-protein alpha s-subunit in rat hypothalamic neurones. J Physiol 1995; 487 (Pt 2): 291-303 [PMID: 8558464]
97. 97 Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660 [PMID: 10604470 DOI: 10.1038/45230]
98. 98 Cheung CK, Wu JC. Role of ghrelin in the pathophysiology of gastrointestinal disease. Gut Liver 2013; 7: 505-512 [PMID: 24073306 DOI: 10.5009/gnl.2013.7.5.505]
99. 99 Hanada T, Toshinai K, Date Y, Kajimura N, Tsukada T, Hayashi Y, Kangawa K, Nakazato M. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism 2004; 53: 84-88 [PMID: 14681847]
100. 100 Kerem M, Ferahkose Z, Yilmaz UT, Pasaoglu H, Ofluoglu E, Bedirli A, Salman B, Sahin TT, Akin M. Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol 2008; 14: 3633-3641 [PMID: 18595130]
101. 101 Takahashi M, Terashima M, Takagane A, Oyama K, Fujiwara H, Wakabayashi G. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol 2009; 14: 315-320 [PMID: 19705241 DOI: 10.1007/s10147-008-0856-1]
102. 102 Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, Kojima M, Kangawa K, Kohno N. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9: 774-778 [PMID: 12576449]
103. 103 Karapanagiotou EM, Polyzos A, Dilana KD, Gratsias I, Boura P, Gkiozos I, Syrigos KN. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2009; 66: 393-398 [PMID: 19282046 DOI: 10.1016/j.lungcan.2009.02.006]
104. 104 Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90: 2920-2926 [PMID: 15713718 DOI: 10.1210/jc.2004-1788]
105. 105 Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hor- mone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med 2006; 45: 127-134 [PMID: 16508225]
106. 106 Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002; 52: 72-91 [PMID: 11929007]
107. 107 Gorter RW. Cancer cachexia and cannabinoids. Forsch Komplementarmed 1999; 6 Suppl 3: 21-22 [PMID: 10575285]
108. 108 Mitchelson F. Pharmacological agents affecting emesis. A review (Part II). Drugs 1992; 43: 443-463 [PMID: 1377113]
109. 109 Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-573 [PMID: 11786587]
110. 110 Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24: 3394-3400 [PMID: 16849753 DOI: 10.1200/ JCO.2005.05.1847]
111. 111 Marks DL, Butler AA, Turner R, Brookhart G, Cone RD. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 2003; 144: 1513-1523 [PMID: 12639936 DOI: 10.1210/ en.2002-221099]
112. 112 Scarlett JM, Marks DL. The use of melanocortin antagonists in cachexia of chronic disease. Expert Opin Investig Drugs 2005; 14: 1233-1239 [PMID: 16185165 DOI: 10.1517/13543784.14.10.1233]
113. 113 DeBoer MD, Marks DL. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab 2006; 2: 459-466 [PMID: 16932335 DOI: 10.1038/ncpendmet0221]
114. 114 Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987; 50: 555-563 [PMID: 3607879]
115. 115 Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia. Cancer Res 1991; 51: 2302-2306 [PMID: 1901758]
116. 116 Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-1684 [PMID: 1569207 DOI: 10.1172/ JCI115767]
117. 117 Costelli P, Carbó N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argilés JM, Baccino FM. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993; 92: 2783-2789 [PMID: 8254032 DOI: 10.1172/ JCI116897]
118. 118 Murray S, Schell K, McCarthy DO, Albertini MR. Tumor growth, weight loss and cytokines in SCID mice. Cancer Lett 1997; 111: 111-115 [PMID: 9022135]
119. 119 Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferongamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 1991; 27: 182-187 [PMID: 1827286]
120. 120 Strassmann G, Kambayashi T. Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther 1995; 1: 107-113 [PMID: 9384667]
121. 121 Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004; 7: 427-434 [PMID: 15192446]
122. 122 Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59: 4493-4501 [PMID: 10493494]
123. 123 Yamamoto N, Kawamura I, Nishigaki F, Tsujimoto S, Naoe Y, Inami M, Elizabeth L, Manda T, Shimomura K. Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon26- induced cachexia in mice. Anticancer Res 1998; 18: 139-144 [PMID: 9568068]
124. 124 Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703 [PMID: 1997652]
125. 125 Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003; 79: 127-132 [PMID: 12697909]
126. 126 Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540-545 [PMID: 15753541 DOI: 10.1136/gut.2004.047563]
127. 127 Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006; 24: 1852-1859 [PMID: 16622259 DOI: 10.1200/JCO.2005.04.2838]
128. 128 Tisdale MJ. Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 105-109 [PMID: 8380931]
129. 129 Anti M, Marra G, Armelao F, Bartoli GM, Ficarelli R, Percesepe A, De Vitis I, Maria G, Sofo L, Rapaccini GL. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 1992; 103: 883-891 [PMID: 1386825]
130. 130 Rose DP, Connolly JM. Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 1993; 85: 1743-1747 [PMID: 8411258]
131. 131 Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, García-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usán L, Casimiro C. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 2007; 97: 823-831 [PMID: 17408522 DOI: 10.1017/S000711450765795X]
132. 132 Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90: 996-1002 [PMID: 14997196 DOI: 10.1038/ sj.bjc.6601620]
133. 133 Barber MD, Ross JA, Preston T, Shenkin A, Fearon KC. Fish oilenriched nutritional supplement attenuates progression of the acutephase response in weight-losing patients with advanced pancreatic cancer. J Nutr 1999; 129: 1120-1125 [PMID: 10356075]
134. 134 Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weightloss in patients with pancreatic cancer. Br J Cancer 1999; 81: 80-86 [PMID: 10487616 DOI: 10.1038/sj.bjc.6690654]
135. 135 Barber MD, McMillan DC, Preston T, Ross JA, Fearon KC. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci (Lond) 2000; 98: 389-399 [PMID: 10731472]
136. 136 Barber MD, Fearon KC. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 2001; 36: 347-351 [PMID: 11383684]
137. 137 Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, Baracos V. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003; 21: 129-134 [PMID: 12506181]
138. 138 Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, Lester E, Kirshner JJ, Vinciguerra V, Paskett E. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 1999; 5: 3942-3947 [PMID: 10632323]
139. 139 Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer 2004; 101: 370-378 [PMID: 15241836 DOI: 10.1002/cncr.20362]
140. 140 Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, Aaronson NK, Voss AC, Tisdale MJ. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52: 1479-1486 [PMID: 12970142]
141. 141 Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 1998; 82: 395-402 [PMID: 9445198]
142. 142 Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, Mac- Donald N, Gagnon B, Novotny PJ, Mailliard JA, Bushey TI, Nair S, Christensen B. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22: 2469-2476 [PMID: 15197210 DOI: 10.1200/JCO.2004.06.024]
143. 143 Kenler AS, Swails WS, Driscoll DF, DeMichele SJ, Daley B, Babineau TJ, Peterson MB, Bistrian BR. Early enteral feeding in postsurgical cancer patients. Fish oil structured lipid-based polymeric formula versus a standard polymeric formula. Ann Surg 1996; 223: 316-333 [PMID: 8604913]
144. 144 Swails WS, Kenler AS, Driscoll DF, DeMichele SJ, Babineau TJ, Utsunamiya T, Chavali S, Forse RA, Bistrian BR. Effect of a fish oil structured lipid-based diet on prostaglandin release from mononuclear cells in cancer patients after surgery. JPEN J Parenter Enteral Nutr 1997; 21: 266-274 [PMID: 9323688]
145. 145 Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KC. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12: S27-S30 [PMID: 8850216]
146. 146 Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000; 36: 177-184 [PMID: 10890028 DOI: 10.1207/S15327914NC3602_6]
147. 147 Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007; (1): CD004597 [PMID: 17253515 DOI: 10.1002/14651858.CD004597. pub2]
148. 148 Anker SD, Coats AJ. How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach. Int J Cardiol 2002; 86: 123-130 [PMID: 12419548]
149. 149 Zuijdgeest-Van Leeuwen SD, Dagnelie PC, Wattimena JL, Van den Berg JW, Van der Gaast A, Swart GR, Wilson JH. Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: effects on lipolysis and lipid oxidation. Clin Nutr 2000; 19: 417-423 [PMID: 11104593 DOI: 10.1054/ clnu.2000.0162]
150. 150 Mazzotta P, Jeney CM. Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated Fatty acids in the management of symptoms, survival, and quality of life. J Pain Symptom Manage 2009; 37: 1069-1077 [PMID: 19054647 DOI: 10.1016/ j.jpainsymman.2008.06.005]
151. 151 Persson C, Glimelius B, Rönnelid J, Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 2005; 21: 170-178 [PMID: 15723745 DOI: 10.1016/j.nut.2004.05.026]
152. 152 Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006; 24: 3401-3407 [PMID: 16849754 DOI: 10.1200/JCO.2005.04.5724]
153. 153 Olaku O, White JD. Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer 2011; 47: 508-514 [PMID: 21185719 DOI: 10.1016/j.ejca.2010.11.018]
154. 154 Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A, Yada T, Maejima Y, Sedbazar U, Sakai T, Hattori T, Kase Y, Inui A. Potentiation of ghrelin signaling attenuates cancer anorexia- anorexiacachexia and prolongs survival. Transl Psychiatry 2011; 1: e23 [PMID: 22832525 DOI: 10.1038/tp.2011.25]
155. 155 Huang CF, Lin SS, Liao PH, Young SC, Yang CC. The immunopharmaceutical effects and mechanisms of herb medicine. Cell Mol Immunol 2008; 5: 23-31 [PMID: 18318991 DOI: 10.1038/ cmi.2008.3]
156. 156 Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607-1609 [PMID: 4135151]
157. 157 Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM, Camoriano JK, Novotny PJ, Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/ cachexia. J Clin Oncol 1999; 17: 3299-3306 [PMID: 10506633]
158. 158 Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, Couch M. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 2008; 30: 67-74 [PMID: 17615567 DOI: 10.1002/ hed.20662]
159. 159 McMillan DC, Wigmore SJ, Fearon KC, O’Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79: 495-500 [PMID: 10027319 DOI: 10.1038/ sj.bjc.6690077]
160. 160 Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 2007; 59: 14-20 [PMID: 17927497 DOI: 10.1080/01635580701365068]
161. 161 Lundholm K, Gelin J, Hyltander A, Lönnroth C, Sandström R, Svaninger G, Körner U, Gülich M, Kärrefors I, Norli B. Antiinflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-5606 [PMID: 7923204]
162. 162 Reid J, Hughes CM, Murray LJ, Parsons C, Cantwell MM. Nonsteroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. Palliat Med 2013; 27: 295-303 [PMID: 22450159 DOI: 10.1177/0269216312441382]
163. 163 Solheim TS, Fearon KC, Blum D, Kaasa S. Non-steroidal antiinflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol 2013; 52: 6-17 [PMID: 23020528 DOI: 10.3109 /0284186X.2012.724536]
164. 164 Kim YS, Sainz RD. Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci 1992; 50: 397-407 [PMID: 1346465]
165. 165 Agbenyega ET, Wareham AC. Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol 1992; 102: 141-145 [PMID: 1351811]
166. 166 Rajab P, Fox J, Riaz S, Tomlinson D, Ball D, Greenhaff PL. Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1076-R1081 [PMID: 10956268]
167. 167 Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK, Isfort RJ. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 2002; 25: 729-734 [PMID: 11994968 DOI: 10.1002/mus.10092]
168. 168 Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 1989; 261: 1-10 [PMID: 2570567]
169. 169 Mersmann HJ. Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci 1998; 76: 160-172 [PMID: 9464897]
170. 170 Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, Ametller E, Argilés JM, López-Soriano FJ. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004; 64: 6725-6731 [PMID: 15374990 DOI: 10.1158/0008-5472.CAN-04-0425]
171. 171 Penna F, Busquets S, Toledo M, Pin F, Massa D, López-Soriano FJ, Costelli P, Argilés JM. Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. J Lipid Res 2013; 54: 3045-3051 [PMID: 23966665 DOI: 10.1194/jlr. M038406]
172. 172 van Halteren HK, Bongaerts GP, Verhagen CA, Kamm YJ, Willems JL, Grutters GJ, Koopman JP, Wagener DJ. Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model. J Cancer Res Clin Oncol 2004; 130: 211-216 [PMID: 14745550 DOI: 10.1007/s00432-003-0526-7]
173. 173 Kanzaki M, Soda K, Gin PT, Kai T, Konishi F, Kawakami M. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine 2005; 32: 234-239 [PMID: 16338141 DOI: 10.1016/j.cyto.2005.10.002]
174. 174 Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005; 93: 425-434 [PMID: 16052213 DOI: 10.1038/sj.bjc.6602725]
175. 175 Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, Kaschina E, Palus S, Pötsch M, von Websky K, Hocher B, Latouche C, Jaisser F, Morawietz L, Coats AJ, Beadle J, Argiles JM, Thum T, Földes G, Doehner W, Hilfiker-Kleiner D, Force T, Anker SD. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 2014; 35: 932-941 [PMID: 23990596 DOI: 10.1093/eurheartj/eht302]
176. 176 de Gramont A, de Gramont A, Chibaudel B, Larsen AK, Tournigand C, André T. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer 2011; 10: 218-226 [PMID: 22122893 DOI: 10.1016/j.clcc.2011.10.001]
177. 177 Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 2006; 15: 1030-1034 [PMID: 16702388 DOI: 10.1158/1055-9965. EPI-05-0538]
178. 178 Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G. Cancer cachexia: traditional therapies and novel molecular mechanismbased approaches to treatment. Curr Treat Options Oncol 2010; 11: 107-117 [PMID: 21128029 DOI: 10.1007/s11864-010-0127-z]
179. 179 Couch M, Lai V, Cannon T, Guttridge D, Zanation A, George J, Hayes DN, Zeisel S, Shores C. Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck 2007; 29: 401-411 [PMID: 17285641 DOI: 10.1002/hed.20447]
180. 180 Lundholm K, Daneryd P, Bosaeus I, Körner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer 2004; 100: 1967-1977 [PMID: 15112279 DOI: 10.1002/cncr.20160]
181. 181 Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 371-385 [PMID: 22345712 DOI: 10.1093/jnci/djr556]
182. 182 Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010; 1: 9-21 [PMID: 21475693 DOI: 10.1007/s13539-010-0007-1]
183. 183 Toledo M, Busquets S, Sirisi S, Serpe R, Orpí M, Coutinho J, Martínez R, López-Soriano FJ, Argilés JM. Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep 2011; 25: 189-193 [PMID: 21109976]
184. 184 Baltgalvis KA, Berger FG, Peña MM, Davis JM, White JP, Carson JA. Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc (Min/+) mouse. Pflugers Arch 2009; 457: 989-1001 [PMID: 18712412 DOI: 10.1007/s00424-008-0574-6]
185. 185 Weber MA, Krakowski-Roosen H, Schröder L, Kinscherf R, Krix M, Kopp-Schneider A, Essig M, Bachert P, Kauczor HU, Hildebrandt W. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol 2009; 48: 116-124 [PMID: 18607877 DOI: 10.1080/02841860802130001]
186. 186 Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F, Adamo S, Coletti D. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer 2010; 10: 363 [PMID: 20615237 DOI: 10.1186/1471-2407-10-363]
187. 187 Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen: Department of Palliative Medicinen/European Palliative Care Research Collaborative, 2010
188. 188 Ardies CM. Exercise, cachexia, and cancer therapy: a molecular rationale. Nutr Cancer 2002; 42: 143-157 [PMID: 12416253 DOI: 10.1207/S15327914NC422_1]
189. 189 al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs 2001; 2: 186-197 [PMID: 11547540]
190. 190 Oldervoll LM, Loge JH, Lydersen S, Paltiel H, Asp MB, Nygaard UV, Oredalen E, Frantzen TL, Lesteberg I, Amundsen L, Hjermstad MJ, Haugen DF, Paulsen Ø, Kaasa S. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16: 1649-1657 [PMID: 21948693 DOI: 10.1634/theoncologist. 2011-0133]
191. 191 Argilés JM, Busquets S, López-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle 2012; 3: 73-76 [PMID: 22565649 DOI: 10.1007/s13539-012-0067-5]
192. 192 Aagaard P. Making muscles “stronger”: exercise, nutrition, drugs. J Musculoskelet Neuronal Interact 2004; 4: 165-174 [PMID: 15615119]
193. 193 Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, Fanelli FR, Doglietto GB, Baccino FM. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003; 237: 384-389 [PMID: 12616123 DOI: 10.1097/00000658-200303000-00013]